Stockscreener 앱 받기
27.43
5.64%
-1.64
시간 외 거래:
27.81
0.38
+1.39%
Avalyn Pharma Inc 주식(AVLN)의 최신 뉴스
Avalyn brings patient feedback on lung fibrosis care to ATS 2026 - Stock Titan
Avalyn to Present Patient-Centered Research on AP01 - GlobeNewswire
Lung disease drug developer Avalyn surges on public debut - MSN
Preferred dividends of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash per share of Avalyn Pharma Inc. – BOATS:AVLN - TradingView
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Avalyn Pharma completes $345 million IPO on nasdaq - Investing.com
Avalyn Pharma completes $345 million IPO on nasdaq By Investing.com - Investing.com Canada
Avalyn Pharma closes $345 million IPO on Nasdaq - Investing.com
Avalyn raises $345M as underwriters take all extra IPO shares - Stock Titan
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Announces Closing of Initial Public Offering and - GlobeNewswire
Avalyn Pharma Inc. (AVLN) Stock Price Today & Analysis - Gotrade
AVLN Price Today: Avalyn Pharma Inc. Stock Price, Quote & Chart | MEXC - MEXC
Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO - Smartkarma
EDGAR Filing Documents for 0001193125-26-197686 - SEC.gov
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to NASDAQ Composite Index - marketscreener.com
Avalyn Pharma raises $300M in IPO, shares surge 64% on first day of trading - The Business Journals
Goodwin, Davis Polk Lead Avalyn's Upsized $300M IPO - Law360
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO - Bloomberg.com
Is Avalyn Pharma (NASDAQ:AVLN) In A Good Position To Invest In Growth? - Yahoo Finance
Pulmonary drug developer Avalyn surges on IPO (AVLN:NASDAQ) - Seeking Alpha
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News
Mists of Avalyn thicken with $300M IPO for inhaled drugs - BioWorld News
Avalyn Pharma prices $300M IPO at $18 per share - MSN
Avalyn Pharma IPO ends oversubscribed with concentrated allocations - Investing.com
Avalyn Pharma Rings the Opening Bell - Nasdaq
Avalyn Pharma Inc (AVLN) Stock Price, News & Analyst Forecast - eToro
Avalyn Sets IPO Price At $18 Per Share - RTTNews
IPO Tracker 2026: Avalyn beats expectations with $300M debut - BioSpace
Avalyn prices upsized IPO at $18 per share, raising $300 million - Investing.com
Avalyn Pharma prices upsized IPO at $18 per share for $300 million - Investing.com
Avalyn Pharma raises $300M in IPO - Axios
Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO - Bloomberg.com
Avalyn Pharma prices upsized IPO at $18 per share - Investing.com
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO - BioPharma Dive
Avalyn Announces Pricing of Upsized Initial Public Offering - The Manila Times
AVLN : Avalyn Pharma Key Company Details - Zacks Investment Research
AVLN : AVALYN PHARMA Key Company Metrics & Non-finance Metrics - Zacks Investment Research
EDGAR Filing Documents for 0001193125-26-189477 - SEC.gov
Avalyn Pharma Inc. Income Statement – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc. Dividends – NASDAQ:AVLN - TradingView
Net income before discontinued operations of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
AVALYN PHARMA INC Balance Sheet – NASDAQ:AVLN - TradingView
Total debt of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Free cash flow of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
AVALYN PHARMA INC Earnings and Revenue – NASDAQ:AVLN - TradingView
Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury - Yahoo Finance
Basic earnings per share (basic EPS) of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Pretax income of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Total revenue of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Total operating expenses of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Operating expenses (excl. COGS) of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Diluted shares outstanding of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Non-operating income (total) of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Operating income of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Total equity of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
EBIT of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Total assets of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Discontinued operations of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Taxes of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
EBITDA of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Gross profit of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Equity in earnings of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash from financing activities of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Diluted earnings per share (diluted EPS) of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Diluted net income available to common stockholders of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Debt to assets ratio of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Return on invested capital % of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Dilution adjustment of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Total liabilities of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Cash from investing activities of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Tangible book value per share of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
0.14%
0.48%
자본화:
|
볼륨(24시간):